All tumors gone – a cancer therapy delivers a welcome surprise
Cancer therapy Colorectal Cancer Checkpoint Inhibitor

All tumors gone – a cancer therapy delivers a welcome surprise

Dr. Talia Henkle
Dr. Talia Henkle

In 10 seconds? A cancer-fighting drug called an immune checkpoint inhibitor (specifically, anti-PD-1) was found to successfully treat 100% of rectal cancer patients in a study of 12 patients without the need for any other cancer treatments.

Yeah, I saw this in the news. Are the results as good as they say? Well, they are certainly exciting and showcase the improved scientific understanding of which patients will respond successfully to certain cancer treatments. (More on this below) But, although the results are impressive, there are a few things to keep in mind when interpreting them. First of all, the drug used in the study, dostarlimab, is an anti-PD1 antibody that exists as a cancer treatment. And while its formulation is new (FDA approved in 2021), other very similar anti-PD-1 antibodies have been successfully used to treat cancer since 2014. So, the treatment type is not new, per se. Second, this was a small study of only 12 patients who were carefully selected for treatment based on tumor-specific genetic factors. Overall this study, exemplifies how researchers can now select patients they ‘expect’ to successfully respond to treatment.


Get unlimited access to our 3-min Digests and other premium features

Choose your plan:

Personal

$99/year

✅ Includes 7-day free trial for new users
✅ Weekly Recap
✅ Daily newsletter
✅ Access 4 topic areas of your choosing
✅ Access all citations and resources
✅ Gain background knowledge with a Quick Dive
✅ The Sparrow Sessions Podcast
✅ No ads
❌ Direct access to the Expert Network
❌ Your questions - answered by an Expert Scientist
❌ 12 hours of consultations with our fabulous experts per year (that’s 1 hour per month!)
❌ Access to all topic areas as we scale the Content Library

We'll send you a reminder email 3 days before your trial ends.

Start my free trial

Professional

$3499/year

✅ Includes 7-day free trial for new users
✅ Weekly Recap
✅ Daily newsletter
✅ Access all citations and resources
✅ Gain background knowledge with a Quick Dive
✅ The Sparrow Sessions Podcast
✅ No ads
✅ Direct access to the Expert Network
✅ Your questions - answered by an Expert Scientist
✅ 12 hours of consultations with our fabulous experts per year (that’s 1 hour per month!)
✅ Access to all topic areas as we scale the Content Library

We'll send you a reminder email 3 days before your trial ends.

Start my free trial